Zinc finger protein A20 protects rats against chronic liver allograft dysfunction

World Journal of Gastroenterology

Volumn 18, Issue 27, 2012, Pages 3537-3550

  Yang, Jie ^a   Xu, Ming Qing ^a   Yan, Lu Nan ^a   Chen, Xiao Bo ^a   Liu, Jiao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Chronic allograft dysfunction; Liver transplantation; Rat; Zinc finger protein A20

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; BILIRUBIN; CASPASE 8; CD40 LIGAND; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; RECOMBINANT PROTEIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; ZINC FINGER PROTEIN A20;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ACTIVATION; CHRONIC LIVER ALLOGRAFT DYSFUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; GENE EXPRESSION; GRAFT DYSFUNCTION; GRAFT RECIPIENT; HOMEOSTASIS; KUPFFER CELL; LIVER ALLOGRAFT FIBROSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT REJECTION; LIVER SINUSOID; LIVER SINUSOID ENDOTHELIAL CELL; LIVER TRANSPLANTATION; MALE; NONHUMAN; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; RAT; STELLATE CELL; SURVIVAL; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

EID: 84864317345     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i27.3537     Document Type: Article

References (50)

1. Blakolmer K, Jain A, Ruppert K, Gray E, Duquesnoy R, Murase N, Starzl TE, Fung JJ, Demetris AJ. Chronic liver allograft rejection in a population treated primarily with tacrolimus as baseline immunosuppression: long-term follow-up and evaluation of features for histopathological staging. Transplantation 2000; 69: 2330-2336.
2. European FK506 Multicentre Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 1994; 344: 423-428.
3. Wong T, Nouri-Aria KT, Devlin J, Portmann B, Williams R. Tolerance and latent cellular rejection in long-term liver tran splant recipients. Hepatology 1998; 28: 443-449.
4. Slapak GI, Saxena R, Portmann B, Gane E, Devlin J, Calne R, Williams R. Graft and systemic disease in long-term survivors of liver transplantation. Hepatology 1997; 25: 195-202.
5. Tashiro H, Fudaba Y, Itoh H, Mizunuma K, Ohdan H, Itamoto T, Asahara T. Hepatocyte growth factor prevents chronic allograft dysfunction in liver-transplanted rats. Transplantation 2003; 76: 761-765.
6. Tilney NL, Whitley WD, Diamond JR, Kupiec-Weglinski JW, Adams DH. Chronic rejection--an undefined conundrum. Transplantation 1991; 52: 389-398.
7. Friedman SL. Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies. N Engl J Med 1993; 328: 1828-1835.
8. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med 1994; 331: 1286-1292.
9. Hellerbrand C, Jobin C, Iimuro Y, Licato L, Sartor RB, Bre nner DA. Inhibition of NFkappaB in activated rat hepatic stellate cells by proteasome inhibitors and an IkappaB super-repressor. Hepatology 1998; 27: 1285-1295.
10. Elsharkawy AM, Wright MC, Hay RT, Arthur MJ, Hughes T, Bahr MJ, Degitz K, Mann DA. Persistent activation of nuclear factor-kappaB in cultured rat hepatic stellate cells involves the induction of potentially novel Rel-like factors and prolonged changes in the expression of IkappaB family proteins. Hepatology 1999; 30: 761-769.
11. Schwabe RF, Schnabl B, Kweon YO, Brenner DA. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol 2001; 166: 6812-6819.
12. Hellerbrand C, Jobin C, Licato LL, Sartor RB, Brenner DA. Cytokines induce NF-kappaB in activated but not in quiescent rat hepatic stellate cells. Am J Physiol 1998; 275: G269-G278.
13. Gaweco AS, Wiesner RH, Yong S, Krom R, Porayko M, Chejfec G, McClatchey KD, Van Thiel DH. CD40L (CD154) expression in human liver allografts during chronic ductopenic rejection. Liver Transpl Surg 1999; 5: 1-7.
14. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996; 97: 1715-1722.
15. Longo CR, Arvelo MB, Patel VI, Daniel S, Mahiou J, Grey ST, Ferran C. A20 protects from CD40-CD40 ligand-mediated endothelial cell activation and apoptosis. Circulation 2003; 108: 1113-1118.
16. Arvelo MB, Badrichani AZ, Stroka DM, Grey ST, Bach FH, Ferran C. A novel function for A20 in smooth muscle cells: inhibition of activation and proliferation. Transplant Proc 1999; 31: 858-859.
17. Patel VI, Daniel S, Longo CR, Shrikhande GV, Scali ST, Czismadia E, Groft CM, Shukri T, Motley-Dore C, Ramsey HE, Fisher MD, Grey ST, Arvelo MB, Ferran C. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia. FASEB J 2006; 20: 1418-1430.
18. Daniel S, Patel VI, Shrikhande GV, Scali ST, Ramsey HE, Csizmadia E, Benhaga N, Fisher MD, Arvelo MB, Ferran C. The universal NF-kappaB inhibitor a20 protects from transplant vasculopathy by differentially affecting apoptosis in endothelial and smooth muscle cells. Transplant Proc 2006; 38: 3225-3227.
19. Brand K, Page S, Walli AK, Neumeier D, Baeuerle PA. Role of nuclear factor-kappa B in atherogenesis. Exp Physiol 1997; 82: 297-304.
20. Opipari AW, Boguski MS, Dixit VM. The A20 cDNA induced by tumor necrosis factor alpha encodes a novel type of zinc finger protein. J Biol Chem 1990; 265: 14705-14708.
21. Arvelo MB, Cooper JT, Longo C, Daniel S, Grey ST, Mahiou J, Czismadia E, Abu-Jawdeh G, Ferran C. A20 protects mice from D-galactosamine/lipopolysaccharide acute toxic lethal hepatitis. Hepatology 2002; 35: 535-543.
22. Longo CR, Patel VI, Shrikhande GV, Scali ST, Csizmadia E, Daniel S, Sun DW, Grey ST, Arvelo MB, Ferran C. A20 protects mice from lethal radical hepatectomy by promoting hepatocyte proliferation via a p21waf1-dependent mechanism. Hepatology 2005; 42: 156-164.
23. Daniel S, Arvelo MB, Patel VI, Longo CR, Shrikhande G, Shukri T, Mahiou J, Sun DW, Mottley C, Grey ST, Ferran C. A20 protects endothelial cells from TNF-, Fas-, and NK-mediated cell death by inhibiting caspase 8 activation. Blood 2004; 104: 2376-2384.
24. Cooper JT, Stroka DM, Brostjan C, Palmetshofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NF-kappaB-dependent mechanism. J Biol Chem 1996; 271: 18068-18073.
25. Beyaert R, Heyninck K, Van Huffel S. A20 and A20-binding proteins as cellular inhibitors of nuclear factor-kappa B-dependent gene expression and apoptosis. Biochem Pharmacol 2000; 60: 1143-1151.
26. Ferran C, Stroka DM, Badrichani AZ, Cooper JT, Wrighton CJ, Soares M, Grey ST, Bach FH. A20 inhibits NF-kappaB activation in endothelial cells without sensitizing to tumor necrosis factor-mediated apoptosis. Blood 1998; 91: 2249-2258.
27. Zhang SQ, Kovalenko A, Cantarella G, Wallach D. Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity 2000; 12: 301-311.
28. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL, Ma A, Koonin EV, Dixit VM. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 2004; 430: 694-699.
29. Liang TB, Man K, Kin-Wah Lee T, Hong-Teng Tsui S, Lo CM, Xu X, Zheng SS, Fan ST, Wong J. Distinct intragraft response pattern in relation to graft size in liver transplantation. Transplantation 2003; 75: 673-678.
30. Ramsey HE, Da Silva CG, Longo CR, Csizmadia E, Studer P, Patel VI, Damrauer SM, Siracuse JJ, Daniel S, Ferran C. A20 protects mice from lethal liver ischemia/reperfusion injury by increasing peroxisome proliferator-activated receptoralpha expression. Liver Transpl 2009; 15: 1613-1621.
31. Avihingsanon Y, Ma N, Csizmadia E, Wang C, Pavlakis M, Giraldo M, Strom TB, Soares MP, Ferran C. Expression of protective genes in human renal allografts: a regulatory response to injury associated with graft rejection. Transplantation 2002; 73: 1079-1085.
32. Xu MQ, Wang W, Xue L, Yan LN. NF-kappaB activation and zinc finger protein A20 expression in mature dendritic cells derived from liver allografts undergoing acute rejection. World J Gastroenterol 2003; 9: 1296-1301.
33. Xu MQ, Yan LN, Gou XH, Li DH, Huang YC, Hu HY, Wang LY, Han L. Zinc finger protein A20 promotes regeneration of small-for-size liver allograft and suppresses rejection and results in a longer survival in recipient rats. J Surg Res 2009; 152: 35-45.
34. Braet F, De Zanger R, Sasaoki T, Baekeland M, Janssens P, Smedsrød B, Wisse E. Assessment of a method of isolation, purification, and cultivation of rat liver sinusoidal endothelial cells. Lab Invest 1994; 70: 944-952.
35. Iwamoto H, Nakamuta M, Tada S, Sugimoto R, Enjoji M, Nawata H. A p160ROCK-specific inhibitor, Y-27632, attenuates rat hepatic stellate cell growth. J Hepatol 2000; 32: 762-770.
36. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
37. Xu J, Xie J, Bao M, Li Z, Yang Z. NF-kappaB/I-kappaB pathway during ischemia reperfusion injury of rat liver. Chin Med J (Engl) 2003; 116: 1146-1149.
38. Fujihara SM, Cleaveland JS, Grosmaire LS, Berry KK, Kennedy KA, Blake JJ, Loy J, Rankin BM, Ledbetter JA, Nadler SG. A D-amino acid peptide inhibitor of NF-kappa B nuclear localization is efficacious in models of inflammatory disease. J Immunol 2000; 165: 1004-1012.
39. Okada M, Okamoto T, Yamada S, Yamada S, Itoh T, Mori A, Saheki K, Takatsuka H, Wada H, Tamura A Y, Fujimori Y, Takemoto Y, Kakishita E. Successful treatment of chronic graft-versus-host disease with sulfasalazine in allogeneic bone marrow transplantation. Acta Haematol 1999; 102: 107-109.
40. May MJ, Ghosh S. Signal transduction through NF-kappa B. Immunol Today 1998; 19: 80-88.
41. Oikawa K, Ohkohchi N, Sato M, Masamume A, Satomi S. Kupffer cells play an important role in the cytokine production and activation of nuclear factors of liver grafts from non-heart-beating donors. Transpl Int 2002; 15: 397-405.
42. Miyagawa-Hayashino A, Tsuruyama T, Egawa H, Haga H, Sakashita H, Okuno T, Toyokuni S, Tamaki K, Yamabe H, Manabe T, Uemoto S. FasL expression in hepatic antigenpresenting cells and phagocytosis of apoptotic T cells by FasL+ Kupffer cells are indicators of rejection activity in human liver allografts. Am J Pathol 2007; 171: 1499-1508.
43. Chen Y, Liu Z, Liang S, Luan X, Long F, Chen J, Peng Y, Yan L, Gong J. Role of Kupffer cells in the induction of tolerance of orthotopic liver transplantation in rats. Liver Transpl 2008; 14: 823-836.
44. Luo D, Vanderkerken K, Bouwens L, Kuppen PJ, Baekeland M, Seynaeve C, Wisse E. The role of adhesion molecules in the recruitment of hepatic natural killer cells (pit cells) in rat liver. Hepatology 1996; 24: 1475-1480.
45. Yamamoto H, Ohdan H, Shintaku S, Asahara T, Ito H, Dohi K. Role of the bcl-2/bax pathway in hepatocyte apoptosis during acute rejection after rat liver transplantation. Transpl Int 1998; 11 Suppl 1: S179-S184.
46. Krams SM, Egawa H, Quinn MB, Villanueva JC, GarciaKennedy R, Martinez OM. Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation 1995; 59: 621-625.
47. Hsieh CL, Obara H, Ogura Y, Martinez OM, Krams SM. NK cells and transplantation. Transpl Immunol 2002; 9: 111-114.
48. Kojima Y, Kawasaki-Koyanagi A, Sueyoshi N, Kanai A, Yagita H, Okumura K. Localization of Fas ligand in cytoplasmic granules of CD8+ cytotoxic T lymphocytes and natural killer cells: participation of Fas ligand in granule exocytosis model of cytotoxicity. Biochem Biophys Res Commun 2002; 296: 328-336.
49. Ariki N, Morimoto Y, Yagi T, Oyama T, Cyouda Y, Sadamori H, Inagaki M, Urushihara N, Iwagaki H, Tanaka N. Activated T cells and soluble molecules in the portal venous blood of patients with cholestatic and hepatitis C viruspositive liver cirrhosis. Possible promotion of Fas/FasLmediated apoptosis in the bile-duct cells and hepatocyte injury. J Int Med Res 2003; 31: 170-180.
50. Wang J, Li W, Min J, Ou Q, Chen J. Fas siRNA reduces apoptotic cell death of allogeneic-transplanted hepatocytes in mouse spleen. Transplant Proc 2003; 35: 1594-1595.